BEIJING (Reuters) – China’s medical products regulator said on Monday it grants conditional approval to Genuine Biotech’s treatment Azvudine to treat adult patients with COVID-19.
The greenlight by the National Medical Products Administrations widened the use of Azvudine, which was approved in July last year to treat certain individuals infected with the HIV-1 virus.
(Reporting by Roxanne Liu and Ryan Woo, Editing by Louise Heavens)
